HRP990042A2 - Pyrrolidine and piperidine derivatives - Google Patents
Pyrrolidine and piperidine derivatives Download PDFInfo
- Publication number
- HRP990042A2 HRP990042A2 HR98102246.0A HRP990042A HRP990042A2 HR P990042 A2 HRP990042 A2 HR P990042A2 HR P990042 A HRP990042 A HR P990042A HR P990042 A2 HRP990042 A2 HR P990042A2
- Authority
- HR
- Croatia
- Prior art keywords
- hydroxy
- formula
- compounds
- phenyl
- pyrrolidin
- Prior art date
Links
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title claims description 9
- 150000003053 piperidines Chemical class 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 61
- 230000004770 neurodegeneration Effects 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 8
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- FDMHLYNPDLYJEQ-UHFFFAOYSA-N 4-[5-(2-phenylethyl)-1,3,5,6,7,7a-hexahydropyrrolo[1,2-c][1,3]oxazol-1-yl]phenol Chemical compound C1=CC(O)=CC=C1C1C2CCC(CCC=3C=CC=CC=3)N2CO1 FDMHLYNPDLYJEQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- WJKBNMVRTYMBRV-UHFFFAOYSA-N 2-fluoro-4-[hydroxy-[5-[2-(4-methoxyphenyl)ethyl]pyrrolidin-2-yl]methyl]phenol Chemical compound C1=CC(OC)=CC=C1CCC1NC(C(O)C=2C=C(F)C(O)=CC=2)CC1 WJKBNMVRTYMBRV-UHFFFAOYSA-N 0.000 claims description 3
- LXJWBQWOTGZWBY-UHFFFAOYSA-N 4-[[5-(2-phenylethyl)pyrrolidin-2-yl]methyl]benzene-1,2-diol Chemical compound C1=C(O)C(O)=CC=C1CC1NC(CCC=2C=CC=CC=2)CC1 LXJWBQWOTGZWBY-UHFFFAOYSA-N 0.000 claims description 3
- RRFABDMVUNCVKO-UHFFFAOYSA-N 4-[[5-[2-(4-methoxyphenyl)ethyl]pyrrolidin-2-yl]methyl]phenol Chemical compound C1=CC(OC)=CC=C1CCC1NC(CC=2C=CC(O)=CC=2)CC1 RRFABDMVUNCVKO-UHFFFAOYSA-N 0.000 claims description 3
- RLQGPVPMWLWMIA-UHFFFAOYSA-N 4-[hydroxy-[5-(2-phenylethyl)pyrrolidin-2-yl]methyl]benzene-1,2-diol Chemical compound C=1C=C(O)C(O)=CC=1C(O)C(N1)CCC1CCC1=CC=CC=C1 RLQGPVPMWLWMIA-UHFFFAOYSA-N 0.000 claims description 3
- VHOASNCSVHLKMN-UHFFFAOYSA-N 4-[hydroxy-[5-(2-phenylethyl)pyrrolidin-2-yl]methyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(N1)CCC1CCC1=CC=CC=C1 VHOASNCSVHLKMN-UHFFFAOYSA-N 0.000 claims description 3
- VFZJMIFPUIRNPE-UHFFFAOYSA-N 4-[hydroxy-[6-[2-(4-methoxyphenyl)ethyl]piperidin-2-yl]methyl]phenol Chemical compound C1=CC(OC)=CC=C1CCC1NC(C(O)C=2C=CC(O)=CC=2)CCC1 VFZJMIFPUIRNPE-UHFFFAOYSA-N 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- ZWQUFQJBQSRJOT-UHFFFAOYSA-N 4-[hydroxy-[5-[2-(4-methoxyphenyl)ethyl]pyrrolidin-2-yl]methyl]phenol Chemical compound C1=CC(OC)=CC=C1CCC1NC(C(O)C=2C=CC(O)=CC=2)CC1 ZWQUFQJBQSRJOT-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 238000006264 debenzylation reaction Methods 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 125000002971 oxazolyl group Chemical class 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- HFBNCFXOVUWMDI-UHFFFAOYSA-N 4-[6-(2-phenylethyl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[2,1-c][1,4]oxazin-1-yl]phenol Chemical compound C1=CC(O)=CC=C1C1C2CCC(CCC=3C=CC=CC=3)N2CCO1 HFBNCFXOVUWMDI-UHFFFAOYSA-N 0.000 description 5
- HOHCLVCBKIGUIG-UHFFFAOYSA-N 6-(2-phenylethyl)-1-(4-phenylmethoxyphenyl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[2,1-c][1,4]oxazine Chemical compound C1CC2C(C=3C=CC(OCC=4C=CC=CC=4)=CC=3)OCCN2C1CCC1=CC=CC=C1 HOHCLVCBKIGUIG-UHFFFAOYSA-N 0.000 description 5
- BDLYEWIRLNVIEN-UHFFFAOYSA-N 6-(2-phenylethyl)-1-(4-phenylmethoxyphenyl)-6,7,8,8a-tetrahydro-1h-pyrrolo[2,1-c][1,4]oxazin-4-one Chemical compound N12C(=O)COC(C=3C=CC(OCC=4C=CC=CC=4)=CC=3)C2CCC1CCC1=CC=CC=C1 BDLYEWIRLNVIEN-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229960004977 anhydrous lactose Drugs 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FAEWQXFFTDROQS-UHFFFAOYSA-N 2-benzyl-5-(2-phenylethyl)pyrrolidine Chemical compound C1CC(CC=2C=CC=CC=2)NC1CCC1=CC=CC=C1 FAEWQXFFTDROQS-UHFFFAOYSA-N 0.000 description 1
- MJSANGQFGKTFPU-UHFFFAOYSA-N 2-hydroxy-5-[hydroxy-[5-[2-(4-methoxyphenyl)ethyl]pyrrolidin-2-yl]methyl]benzamide Chemical compound C1=CC(OC)=CC=C1CCC1NC(C(O)C=2C=C(C(O)=CC=2)C(N)=O)CC1 MJSANGQFGKTFPU-UHFFFAOYSA-N 0.000 description 1
- FLWWKBVIUMBHIM-UHFFFAOYSA-N 4-[2-[5-[hydroxy(phenyl)methyl]pyrrolidin-2-yl]ethyl]phenol Chemical compound C=1C=CC=CC=1C(O)C(N1)CCC1CCC1=CC=C(O)C=C1 FLWWKBVIUMBHIM-UHFFFAOYSA-N 0.000 description 1
- HDCUHFYAULOMTO-UHFFFAOYSA-N 4-[[1-butyl-5-(2-phenylethyl)pyrrolidin-2-yl]methyl]benzene-1,2-diol Chemical compound C1CC(CC=2C=C(O)C(O)=CC=2)N(CCCC)C1CCC1=CC=CC=C1 HDCUHFYAULOMTO-UHFFFAOYSA-N 0.000 description 1
- WDICQCQUWYZYDQ-UHFFFAOYSA-N 4-[[5-(2-phenylethyl)-1-propylpyrrolidin-2-yl]methyl]benzene-1,2-diol Chemical compound C1CC(CC=2C=C(O)C(O)=CC=2)N(CCC)C1CCC1=CC=CC=C1 WDICQCQUWYZYDQ-UHFFFAOYSA-N 0.000 description 1
- DCIOOMQJSUQUTN-UHFFFAOYSA-N 4-[[5-[2-(4-hydroxyphenyl)ethyl]-1-propylpyrrolidin-2-yl]methyl]benzene-1,2-diol Chemical compound C1CC(CC=2C=C(O)C(O)=CC=2)N(CCC)C1CCC1=CC=C(O)C=C1 DCIOOMQJSUQUTN-UHFFFAOYSA-N 0.000 description 1
- ATFYRLFHFXKNRY-UHFFFAOYSA-N 4-[[5-[2-(4-hydroxyphenyl)ethyl]pyrrolidin-2-yl]methyl]benzene-1,2-diol Chemical compound C1=CC(O)=CC=C1CCC1NC(CC=2C=C(O)C(O)=CC=2)CC1 ATFYRLFHFXKNRY-UHFFFAOYSA-N 0.000 description 1
- RTPWAGKTOIOCCG-UHFFFAOYSA-N 4-[[5-[2-(4-methoxyphenyl)ethyl]pyrrolidin-2-yl]methyl]benzene-1,2-diol Chemical compound C1=CC(OC)=CC=C1CCC1NC(CC=2C=C(O)C(O)=CC=2)CC1 RTPWAGKTOIOCCG-UHFFFAOYSA-N 0.000 description 1
- CLNJYIYJRFIVGL-UHFFFAOYSA-N 4-[hydroxy-[5-[2-(4-hydroxyphenyl)ethyl]pyrrolidin-2-yl]methyl]benzene-1,2-diol Chemical compound C=1C=C(O)C(O)=CC=1C(O)C(N1)CCC1CCC1=CC=C(O)C=C1 CLNJYIYJRFIVGL-UHFFFAOYSA-N 0.000 description 1
- BNZCSMHYSNBOIB-UHFFFAOYSA-N 4-[hydroxy-[5-[2-(4-methoxyphenyl)ethyl]pyrrolidin-2-yl]methyl]-2-methylsulfanylphenol Chemical compound C1=CC(OC)=CC=C1CCC1NC(C(O)C=2C=C(SC)C(O)=CC=2)CC1 BNZCSMHYSNBOIB-UHFFFAOYSA-N 0.000 description 1
- ZEEDTJMSINEVLH-UHFFFAOYSA-N 5-[[5-[2-(2,5-dimethoxyphenyl)ethyl]pyrrolidin-2-yl]-hydroxymethyl]-2-hydroxybenzamide Chemical compound COC1=CC=C(OC)C(CCC2NC(CC2)C(O)C=2C=C(C(O)=CC=2)C(N)=O)=C1 ZEEDTJMSINEVLH-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DJRCTCAQZWVMQY-UHFFFAOYSA-N [5-[2-(1,3-benzodioxol-5-yl)ethyl]pyrrolidin-2-yl]-phenylmethanol Chemical compound C1CC(CCC=2C=C3OCOC3=CC=2)NC1C(O)C1=CC=CC=C1 DJRCTCAQZWVMQY-UHFFFAOYSA-N 0.000 description 1
- JAEHPESDRKXQOH-UHFFFAOYSA-N [5-[2-(4-methoxyphenyl)ethyl]pyrrolidin-2-yl]-phenylmethanol Chemical compound C1=CC(OC)=CC=C1CCC1NC(C(O)C=2C=CC=CC=2)CC1 JAEHPESDRKXQOH-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- IVKNUIVDQMARCO-UHFFFAOYSA-N oxazin-4-one Chemical compound O=C1C=CON=C1 IVKNUIVDQMARCO-UHFFFAOYSA-N 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XEUPOKYEOJYHDE-UHFFFAOYSA-N phenyl-[5-(2-phenylethyl)pyrrolidin-2-yl]methanol Chemical compound C=1C=CC=CC=1C(O)C(N1)CCC1CCC1=CC=CC=C1 XEUPOKYEOJYHDE-UHFFFAOYSA-N 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- -1 t- butyl Chemical group 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000009723 vascular congestion Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98102246 | 1998-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP990042A2 true HRP990042A2 (en) | 2000-02-29 |
Family
ID=8231382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR98102246.0A HRP990042A2 (en) | 1998-02-10 | 1999-02-09 | Pyrrolidine and piperidine derivatives |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6015824A (xx) |
| EP (1) | EP0937458B1 (xx) |
| JP (1) | JP3142527B2 (xx) |
| KR (1) | KR100319249B1 (xx) |
| CN (1) | CN1144789C (xx) |
| AR (1) | AR018077A1 (xx) |
| AT (1) | ATE285766T1 (xx) |
| AU (1) | AU748335B2 (xx) |
| BR (1) | BR9900742A (xx) |
| CA (1) | CA2260698A1 (xx) |
| CZ (1) | CZ41099A3 (xx) |
| DE (1) | DE69922858T2 (xx) |
| DK (1) | DK0937458T3 (xx) |
| ES (1) | ES2245808T3 (xx) |
| HR (1) | HRP990042A2 (xx) |
| HU (1) | HUP9900275A3 (xx) |
| ID (1) | ID23456A (xx) |
| IL (2) | IL128389A0 (xx) |
| MA (1) | MA26607A1 (xx) |
| NO (1) | NO990609L (xx) |
| NZ (1) | NZ334081A (xx) |
| PE (1) | PE20000276A1 (xx) |
| PL (1) | PL331336A1 (xx) |
| PT (1) | PT937458E (xx) |
| SG (1) | SG74120A1 (xx) |
| TR (1) | TR199900286A2 (xx) |
| YU (1) | YU5899A (xx) |
| ZA (1) | ZA991038B (xx) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2793245B1 (fr) * | 1999-05-05 | 2002-10-11 | Adir | Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6369078B1 (en) * | 1999-08-31 | 2002-04-09 | J. Phillip Bowen | Solenopsin derivatives and analogues as fire ant suppressants |
| PT1278728E (pt) * | 2000-04-20 | 2004-10-29 | Hoffmann La Roche | Derivados de pirrolidina e de piperidina e sua utilizacao no tratamento de disturbios neurodegenerativos |
| JP2004516295A (ja) | 2000-12-21 | 2004-06-03 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | サブタイプ選択的なｎ−メチル−ｄ−アスパラギン酸拮抗薬としてのピペリジン誘導体 |
| MXPA02002749A (es) | 2001-03-27 | 2002-10-28 | Warner Lambert Co | Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato. |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| KR20100135847A (ko) * | 2008-03-27 | 2010-12-27 | 에보텍 뉴로사이언시즈 게엠베하 | Ｎｍｄａ ｎｒ２ｂ―서브타입 선택적 길항제를 사용한 질병 치료 방법 |
| BR112012004333A2 (pt) * | 2009-08-27 | 2015-09-08 | Merck Sharp & Dohme | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. |
| WO2011025690A1 (en) * | 2009-08-27 | 2011-03-03 | Merck Sharp & Dohme Corp. | Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941796A (en) * | 1970-05-21 | 1976-03-02 | Minnesota Mining And Manufacturing Company | α-(Hydroxy and alkoxy substituted)phenyl-α-(2-piperidinyl)-methanols |
| US4407670A (en) * | 1980-02-28 | 1983-10-04 | National Research Development Corporation | Biocidal compounds and compositions |
| US4342692A (en) * | 1980-10-20 | 1982-08-03 | Usv Pharmaceutical Corporation | Pyrrolidines |
| DK328382A (da) * | 1981-07-22 | 1983-01-23 | Syntex Inc | Fremgangsmaade til fremstilling af antihypertensive midler |
| IL70752A0 (en) * | 1983-01-24 | 1984-06-29 | Syntex Inc | (+-)2-(3,4-methylenedioxyphenethyl)-5-(3-carbamoyl-alpha,4-dihydroxybenzyl)pyrrolidines and salts thereof,their preparation and pharmaceutical compositions containing them |
| AU2369984A (en) * | 1983-01-24 | 1984-07-26 | Syntex (U.S.A.) Inc. | Pyridine derivatives |
| US4569941A (en) * | 1983-03-21 | 1986-02-11 | Usv Pharmaceutical Corp. | Method of using phenyl-alkylene-2-pyridyl derivatives to increase cardiac contractility in a mammal |
| US4548951A (en) * | 1983-04-21 | 1985-10-22 | Syntex (U.S.A.) Inc. | Hypotensive benzoxathiole pyrrolidines |
| US4558066A (en) * | 1984-05-17 | 1985-12-10 | Syntex (U.S.A.) Inc. | Treatment and prevention of ocular hypertension |
| US4632929A (en) * | 1985-01-17 | 1986-12-30 | Usv Pharmaceutical Corp. | Method of hypertensive treatment using phenyl-alkylene-2-pyridyl derivatives |
-
1999
- 1999-01-20 US US09/234,266 patent/US6015824A/en not_active Expired - Fee Related
- 1999-02-02 PT PT99102078T patent/PT937458E/pt unknown
- 1999-02-02 DE DE69922858T patent/DE69922858T2/de not_active Expired - Fee Related
- 1999-02-02 DK DK99102078T patent/DK0937458T3/da active
- 1999-02-02 ES ES99102078T patent/ES2245808T3/es not_active Expired - Lifetime
- 1999-02-02 EP EP99102078A patent/EP0937458B1/en not_active Expired - Lifetime
- 1999-02-02 AT AT99102078T patent/ATE285766T1/de not_active IP Right Cessation
- 1999-02-05 CZ CZ99410A patent/CZ41099A3/cs unknown
- 1999-02-05 MA MA25457A patent/MA26607A1/fr unknown
- 1999-02-05 CA CA002260698A patent/CA2260698A1/en not_active Abandoned
- 1999-02-05 NZ NZ334081A patent/NZ334081A/xx unknown
- 1999-02-05 IL IL12838999A patent/IL128389A0/xx unknown
- 1999-02-05 BR BR9900742-8A patent/BR9900742A/pt not_active IP Right Cessation
- 1999-02-06 KR KR1019990004058A patent/KR100319249B1/ko not_active IP Right Cessation
- 1999-02-08 AR ARP990100528A patent/AR018077A1/es unknown
- 1999-02-08 SG SG1999000363A patent/SG74120A1/en unknown
- 1999-02-08 PE PE1999000101A patent/PE20000276A1/es not_active Application Discontinuation
- 1999-02-08 AU AU16354/99A patent/AU748335B2/en not_active Ceased
- 1999-02-08 JP JP11029850A patent/JP3142527B2/ja not_active Expired - Fee Related
- 1999-02-08 HU HU9900275A patent/HUP9900275A3/hu unknown
- 1999-02-09 ZA ZA9901038A patent/ZA991038B/xx unknown
- 1999-02-09 HR HR98102246.0A patent/HRP990042A2/hr not_active Application Discontinuation
- 1999-02-09 NO NO990609A patent/NO990609L/no not_active Application Discontinuation
- 1999-02-09 YU YU5899A patent/YU5899A/sh unknown
- 1999-02-09 PL PL99331336A patent/PL331336A1/xx unknown
- 1999-02-09 ID IDP990095A patent/ID23456A/id unknown
- 1999-02-10 CN CNB991018001A patent/CN1144789C/zh not_active Expired - Fee Related
- 1999-02-10 TR TR1999/00286A patent/TR199900286A2/xx unknown
- 1999-07-28 US US09/362,932 patent/US6153624A/en not_active Expired - Fee Related
-
2001
- 2001-07-19 IL IL14445601A patent/IL144456A0/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69329887T2 (de) | Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems | |
| AU2021200164B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| JP6517340B2 (ja) | ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用 | |
| WO2007010383A1 (ja) | 新規なヘテロシクリデンアセトアミド誘導体 | |
| HU228594B1 (en) | Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same | |
| KR20080082250A (ko) | 도파민 ｄ4 수용체 길항제인 신규 피페라지닐프로필피라졸유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
| CN102036967A (zh) | 作为5-ht6拮抗剂的芳基磺酰基吡唑啉甲脒衍生物 | |
| CN110088093A (zh) | 酰基磺酰胺NaV1.7抑制剂 | |
| HRP990042A2 (en) | Pyrrolidine and piperidine derivatives | |
| EP3174880A1 (en) | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors | |
| CN113166081A (zh) | 用于治疗与nlrp活性相关的病症的化合物和组合物 | |
| CN1042225C (zh) | 新的取代的异噁唑衍生物的制备方法 | |
| WO2008096136A1 (en) | Combinations with a muscarinic receptor antagonist | |
| DE60004543T2 (de) | Benzisoxazolyl-, pyridoisoxazolyl- und benzthienyl-phenoxy derivate als d4 antagonisten | |
| AU2007263083B2 (en) | Substituted phenyl methanone derivatives | |
| CN114761000A (zh) | Cdk5的取代的1,6-萘啶抑制剂 | |
| KR20220075335A (ko) | 항균 화합물 | |
| MXPA99001382A (en) | Derivatives of pirrolidine and piperid | |
| CN110290792A (zh) | 吗啡喃衍生物和其用于治疗自体免疫、发炎或感染相关的障碍的组合物 | |
| KR101467649B1 (ko) | 신경계 질환에 대한 테트라하이드로-피란 유도체 | |
| DE20203103U1 (de) | Serotonin-Wiederaufnahme-Inhibitoren | |
| JPS6160612A (ja) | 制癌効果増強剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20010209 Year of fee payment: 3 |
|
| ODBI | Application refused |